Entrada Therapeutics, Inc. (TRDA) Dividend History

Company News

• Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

  Entrada Therapeutics announced the recipients of its second annual DREAMS Grant Program, awarding $25,000 each to three U.S. non-profit organizations - CureDuchenne, The Little Hercules Foundation, and Walking Strong - to support programs advancing diversity, equity, inclusion, and accessibility within the Duchenne community.

  GlobeNewswire Inc.
• Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top

  Nektar Therapeutics reported a wider-than-expected loss in Q2 2024, despite a 14.6% increase in total revenues. The company's lead pipeline candidate, rezpegaldesleukin, is progressing through clinical trials for autoimmune and inflammatory diseases.

  Zacks Investment Research

  Featured Companies: EXAS LLY NKTR
• Entrada Therapeutics Announces $100 Million Registered Direct Offering

  – The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm – – The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm –

  GlobeNewswire Inc.
• Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

  – ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physical exams or laboratory assessments –

  GlobeNewswire Inc.
• Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

  BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL. The fireside chat will be held on Monday, June 10, 2024, at 4:00 p.m. Eastern Time.

  GlobeNewswire Inc.